Description
(AWP Alliance News) - Galenica confirmed its 2026 outlook for sales growth of 5%-7% and adjusted EBIT growth of 6%-8%. The dividend is expected to be at least equal to the previous year's level. Sales rose 5.7% to CHF 3.17 billion in the first nine months, driven by pharmacies, home care and the integration of Diagnostics. Wholesale growth is expected to accelerate in the fourth quarter following temporary product-range restrictions during an ERP migration.
https://www.publicnow.com/view/D24C7CB736DBB0339E98EA083FAB3D85F83AE870…
Disclaimer: This news brief was created using generative artificial intelligence. Galenica AG published the original content used to generate this news brief via EQS News on October 22, 2026, and is solely responsible for the information contained therein.
